Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses

Franco Lori, Andrea Foli, Renato Maserati, Elena Seminari, Jianqing Xu, Lucia Whitman, Elisabetta Ravot, Francesco Alberici, Lucia Lopalco, Julianna Lisziewicz

Research output: Contribution to journalArticle

Abstract

Purpose: To study whether and under what circumstances HIV can be controlled in chronically infected patients. Method: Nine patients treated with hydroxyurea and didanosine (PANDAs) were compared with 7 patients on highly active antiretroviral therapy (HAART) during an 8-week treatment interruption. Both groups had similar baseline viral load, CD4 count, and length of treatment. Treatment was resumed if viral rebound > 10,000 copies/mL (virological failure) or CD4 count decrease below 200 cells/mm3 (immunological failure) occurred in two consecutive measurements. Results: None of the PANDAs failed. Viral rebound was spontaneously contained, and CD4 count remained stable. Four out of 7 patients in the HAART group failed to control HIV by week 6 and had to restart therapy due to either viremia rebound or CD4 decrease. Before therapy interruption, the PANDAs had a vigorous HIV-specific T cell immune response (median CD4VIR 1.2%), while the HAART-treated patients did not (median CD4VIR 0.2%) (CD4VIR represents the percentage of HIV-specific CD4 subpopulation expressing IFN-γ within the total CD4 population [CD3+, CD4+, IFN-γ+]). This difference was statistically significant (p = .002). Conclusion: This study shows that HIV can be controlled during therapy interruption in patients with established infection, and that control of viral replication correlates with vigorous anti-HIV specific immune responses.

Original languageEnglish
Pages (from-to)115-124
Number of pages10
JournalHIV Clinical Trials
Volume3
Issue number2
Publication statusPublished - 2002

Fingerprint

HIV
T-Lymphocytes
Highly Active Antiretroviral Therapy
CD4 Lymphocyte Count
Therapeutics
Didanosine
Hydroxyurea
Viremia
Infection Control
Viral Load
Population

Keywords

  • Anti-HIV immune response
  • Hydroxyurea
  • STI

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. / Lori, Franco; Foli, Andrea; Maserati, Renato; Seminari, Elena; Xu, Jianqing; Whitman, Lucia; Ravot, Elisabetta; Alberici, Francesco; Lopalco, Lucia; Lisziewicz, Julianna.

In: HIV Clinical Trials, Vol. 3, No. 2, 2002, p. 115-124.

Research output: Contribution to journalArticle

Lori, Franco ; Foli, Andrea ; Maserati, Renato ; Seminari, Elena ; Xu, Jianqing ; Whitman, Lucia ; Ravot, Elisabetta ; Alberici, Francesco ; Lopalco, Lucia ; Lisziewicz, Julianna. / Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. In: HIV Clinical Trials. 2002 ; Vol. 3, No. 2. pp. 115-124.
@article{20700ad4317948158b8ce639ba9124a1,
title = "Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses",
abstract = "Purpose: To study whether and under what circumstances HIV can be controlled in chronically infected patients. Method: Nine patients treated with hydroxyurea and didanosine (PANDAs) were compared with 7 patients on highly active antiretroviral therapy (HAART) during an 8-week treatment interruption. Both groups had similar baseline viral load, CD4 count, and length of treatment. Treatment was resumed if viral rebound > 10,000 copies/mL (virological failure) or CD4 count decrease below 200 cells/mm3 (immunological failure) occurred in two consecutive measurements. Results: None of the PANDAs failed. Viral rebound was spontaneously contained, and CD4 count remained stable. Four out of 7 patients in the HAART group failed to control HIV by week 6 and had to restart therapy due to either viremia rebound or CD4 decrease. Before therapy interruption, the PANDAs had a vigorous HIV-specific T cell immune response (median CD4VIR 1.2{\%}), while the HAART-treated patients did not (median CD4VIR 0.2{\%}) (CD4VIR represents the percentage of HIV-specific CD4 subpopulation expressing IFN-γ within the total CD4 population [CD3+, CD4+, IFN-γ+]). This difference was statistically significant (p = .002). Conclusion: This study shows that HIV can be controlled during therapy interruption in patients with established infection, and that control of viral replication correlates with vigorous anti-HIV specific immune responses.",
keywords = "Anti-HIV immune response, Hydroxyurea, STI",
author = "Franco Lori and Andrea Foli and Renato Maserati and Elena Seminari and Jianqing Xu and Lucia Whitman and Elisabetta Ravot and Francesco Alberici and Lucia Lopalco and Julianna Lisziewicz",
year = "2002",
language = "English",
volume = "3",
pages = "115--124",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses

AU - Lori, Franco

AU - Foli, Andrea

AU - Maserati, Renato

AU - Seminari, Elena

AU - Xu, Jianqing

AU - Whitman, Lucia

AU - Ravot, Elisabetta

AU - Alberici, Francesco

AU - Lopalco, Lucia

AU - Lisziewicz, Julianna

PY - 2002

Y1 - 2002

N2 - Purpose: To study whether and under what circumstances HIV can be controlled in chronically infected patients. Method: Nine patients treated with hydroxyurea and didanosine (PANDAs) were compared with 7 patients on highly active antiretroviral therapy (HAART) during an 8-week treatment interruption. Both groups had similar baseline viral load, CD4 count, and length of treatment. Treatment was resumed if viral rebound > 10,000 copies/mL (virological failure) or CD4 count decrease below 200 cells/mm3 (immunological failure) occurred in two consecutive measurements. Results: None of the PANDAs failed. Viral rebound was spontaneously contained, and CD4 count remained stable. Four out of 7 patients in the HAART group failed to control HIV by week 6 and had to restart therapy due to either viremia rebound or CD4 decrease. Before therapy interruption, the PANDAs had a vigorous HIV-specific T cell immune response (median CD4VIR 1.2%), while the HAART-treated patients did not (median CD4VIR 0.2%) (CD4VIR represents the percentage of HIV-specific CD4 subpopulation expressing IFN-γ within the total CD4 population [CD3+, CD4+, IFN-γ+]). This difference was statistically significant (p = .002). Conclusion: This study shows that HIV can be controlled during therapy interruption in patients with established infection, and that control of viral replication correlates with vigorous anti-HIV specific immune responses.

AB - Purpose: To study whether and under what circumstances HIV can be controlled in chronically infected patients. Method: Nine patients treated with hydroxyurea and didanosine (PANDAs) were compared with 7 patients on highly active antiretroviral therapy (HAART) during an 8-week treatment interruption. Both groups had similar baseline viral load, CD4 count, and length of treatment. Treatment was resumed if viral rebound > 10,000 copies/mL (virological failure) or CD4 count decrease below 200 cells/mm3 (immunological failure) occurred in two consecutive measurements. Results: None of the PANDAs failed. Viral rebound was spontaneously contained, and CD4 count remained stable. Four out of 7 patients in the HAART group failed to control HIV by week 6 and had to restart therapy due to either viremia rebound or CD4 decrease. Before therapy interruption, the PANDAs had a vigorous HIV-specific T cell immune response (median CD4VIR 1.2%), while the HAART-treated patients did not (median CD4VIR 0.2%) (CD4VIR represents the percentage of HIV-specific CD4 subpopulation expressing IFN-γ within the total CD4 population [CD3+, CD4+, IFN-γ+]). This difference was statistically significant (p = .002). Conclusion: This study shows that HIV can be controlled during therapy interruption in patients with established infection, and that control of viral replication correlates with vigorous anti-HIV specific immune responses.

KW - Anti-HIV immune response

KW - Hydroxyurea

KW - STI

UR - http://www.scopus.com/inward/record.url?scp=0036092039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036092039&partnerID=8YFLogxK

M3 - Article

C2 - 11976989

AN - SCOPUS:0036092039

VL - 3

SP - 115

EP - 124

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 2

ER -